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Abstract
Acne vulgaris is the most common skin disease in adolescents and young adults and 
has serious influence on quality of life of the patients. Acne vulgaris is the most com-
mon skin disease in adolescents and young adults and has serious influence on quality 
of life of the patients. The initial lesions of acne are the microcomedones that can be 
observed histologically in normal-appearing skin. The first step in the treatment of acne 
is to understand the pathophysiology of disease and to act on the factors involved in 
the development of acne. Increased sebum secretion from sebaceous glands, secretion 
of inflammatory mediators, altered keratinization and follicular plugging, and follicular 
colonization of Propionibacterium acnes are major four steps of acne pathogenesis. Topical 
retinoids have multiple effects in the treatment of acne and act on more than one factor 
implicated in the etiology of acne. They prevent the formation of microcomedones and 
reduce their number, reduce macrocomedones, promote the normal desquamation of fol-
licular epithelium, exert anti-inflammatory effects, enhance the penetration of other topi-
cal acne drugs, and prolong the remission periods of acne by inhibiting the formation of 
microcomedone formation and preventing the development of new lesions and bacterial 
resistance. Therefore, topical retinoids have been the first-line treatment for most forms 
of acne vulgaris either alone or together with other agents.
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1. Acne
1.1. Introduction
Acne vulgaris is the most common skin disease in adolescents and young adults with 70–95% 
prevalence rate. Adult or postadolescent acne occurs in 12–14% of this population and is seen 
as the continuation of acne from adolescence into adulthood or starts in the adult life [1, 2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which per its unrestric ed use,
distribution, a d reprodu tion in any edium, provid d the original work is prope ly cited.
Acne has a serious influence on quality of life of the patients. The negative impact of acne 
on behavioral and social functions has found to be greater than medical conditions such as 
asthma and epilepsy. Additionally, compared to unemployment, acne has been shown to 
be more highly associated with anxiety and depression [2, 3]. Fortunately, it is possible to 
improve the quality of life of patients with successful treatment. Over the past few decades, a 
large spectrum of local and systemic drugs has been introduced and a lot of efforts have been 
devoted to reach a consensus on the treatment approach of acne. As new drugs are constantly 
being added to the list, it is critical to update the current recommendations.
1.2. The global alliance to improve outcomes in acne
The Global Alliance to Improve Outcomes in Acne Group (“Global Alliance”) is an interna-
tional group of dermatologists with clinical and research expertise in acne vulgaris. The first 
consensus guidelines were published in 2003 in JAAD and were very well received as an evi-
dence-based and thoughtful document [1]. In the 2009 and 2016 guidelines updated informa-
tion on pathogenesis, mechanism of action of therapies, and clinical results are presented [2, 4].
For this purpose, Global Alliance to Improve Outcomes in Acne Group (“Global Alliance”) 
was formed and the recommendations of the group have been published in 2003 as a supple-
ment in the Journal of the Academy of Dermatology [2]. In the light of novel evidence-based 
studies, these recommendations have been updated recently [4]. On the other hand, racial and 
regional differences may affect the therapeutic approach to acne. Accordingly, in this ongoing 
process regional treatment guidelines are also being published [1, 2, 5–10].
1.3. Clinical features of acne vulgaris
Acne vulgaris is characterized by the presence of comedones and suggested to be a chronic 
disease. It has been traditionally thought that comedones are the noninflammatory lesions 
which present as either open or closed form. Inflammatory lesions of acne are papules, pus-
tules, and nodules. In the previous guidelines, acne was graded into four levels as follows 
“Comedonal acne, mild to moderate papulopustular acne, severe papulopustular/moderate 
nodular acne, severe nodular acne/acne conglobata” [1, 7].
In the last guideline [4], acne has been divided simply as “Mild, moderate, and severe”.
1.4. Pathophysiology of acne
The first step in the treatment of acne is to understand the pathophysiology of disease and 
to act on all factors involved in the development of acne. The initial lesions of acne are the 
microcomedones that already exist in normal-appearing skin. These microcomedones can 
only be observed histologically [1–3, 8]. Additionally, the role of inflammatory cytokine such 
as interleukin-1 (IL-1), relative deficiency of linoleic acid, and hormonal and genetic factors 
has been reported [7].
Four major steps that have been hypothesized in the pathogenesis of acne are outlined in 
Table 1. Although the inflammatory step was previously believed to occur at the end of these 
stages, now it is thought to occur after the increased sebum secretion from sebaceous glands 
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because of the proinflammatory properties of lipids of hyperseborrhea as well as some other 
factors including excess androgen and smoking [1–4, 11].
1.5. Topical treatment of acne
Reviewing the guidelines on the treatment of acne, a recommended common approach is 
outlined in Table 2 [1–4].
There is a large spectrum of topical agents for the treatment of acne (Table 3).
1.6. The importance of topical retinoids in the treatment of acne
Topical retinoids have multiple effects in the treatment of acne and act on more than one fac-
tor implicated in the etiology of acne (Table 4) [1–4, 12–14].
Topical retinoids have been the first-line treatment for most forms of acne vulgaris. They 
are used either alone or together with other agents as a first-line treatment in the treatment 
of acne forms other than severe nodular acne and acne conglobata. Alternative retinoids are 
included in alternative treatment options as well. In maintenance treatment, topical retinoids 
are used alone or in combination with BPO [1–4].
Increased sebum secretion from sebaceous glands
Secretion of inflammatory mediators
Altered keratinization and follicular plugging
Follicular colonization of P. acnes*
*P. acnes:  Propionibacterium acnes
Table 1. Four major steps in the pathogenesis of acne.
Start with topical treatment, if appropriate
Give systemic treatment when necessary
Limit the use of local and systemic antibiotic concomitantly OR add topical BPO*
*BPO: Benzoyl peroxide
Table 2. Recommended general approach for the treatment of acne.
1. Antimicrobials: Azelaic acid (20%), BPO, clindamycin, dapsone (5%), erythromycin, sodium sulfacetamide, sulfur
2. Topical retinoids: Isotretinoin, tretinoin, adapalene, tazarotene
3. Combination drugs: Adapalene-benzoyl peroxide, BPO-clindamycin, BPO-erythromycin, sodium sulfacetamide-
sulfur, tretinoin-clindamycin
4. Keratolytic agents: Salicylic acid
Table 3. Topical agents for the treatment of acne.





Retinoids are vitamin A (retinol) or functional analogs with vitamin A activity. The abnormal 
keratinization in animals with vitamin A deficiency has exposed the importance of vitamin A 
in antikeratinization. As the systemic retinols given in effective dose have resulted in severe 
side effects, synthetic retinoids and their topical forms have been developed with similar 
clinical effect and fewer side effects. The first retinoid synthesized is all-trans-retinoic acid 
(ATRA, tretinoin) but as it has no significant advantages over retinol, it is used generally in 
topical form. ATRA is the natural metabolite of retinol. Isotretinoin has both systemic and 
topical forms. Today various topical retinoids are available for different purposes [14–16]. 
Human skin has retinoid receptors, belonging to thyroid receptor family, which have the 
capacity to store and metabolize retinoids [17]. The biologic effects of topical retinoids are 
mediated through nuclear hormone receptors and cytosolic binding proteins because human 
skin expresses RAR (RAR-γ > RAR-α) and RXR (RXR-α > RXR-β) [14–16]. Table 5 outlines 
retinoid receptors and their main endogenous ligands.
2.2. Topical retinoids used in the treatment of acne
Tretinoin and isotretinoin are the first-generation retinoids whereas adapalene and tazaro-
tene are the third-generation retinoids. Retinaldehyde and retinol are found in cosmetic 
formulations [5]. Commercially available topical retinoids for acne treatment are presented 
in Table 6.
1. Prevent the formation of microcomedones and reduce their number
2. Reduce macrocomedones
3. Promote the normal desquamation of follicular epithelium
4. Exert anti-inflammatory effects
5. Enhance the penetration of other drugs
6. Prolong the remission periods of acne by inhibiting the of microcomedone formation and preventing the develop-
ment of new lesions
7. Prevents bacterial resistance
Table 4. Multiple effects of topical retinoids in the treatment of acne.
The receptors of retinoids Main endogenous ligand
RAR α, β, γ Retinoic acid, 9-cis retinoic acid
RXR α, β, γ 9-cis retinoic acid
RAR, retinoic acid receptor; RXR, retinoid X receptor.
Table 5. Retinoid receptors and their endogenous ligands.
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2.2.1. Tretinoin
Tretinoin is the first retinoid studied and has been used more than 30 years in the treatment 
of acne. It induces the breakage of bonds between keratinized cells and enables the disinte-
gration and the removal of the keratin plug. Besides comedolytic effect, it exerts anti-inflam-
matory effect; however, it does not have an effect on sebaceous gland activity. It binds to 
RARs on cytosol and regulates the expression of genes after moving to nucleus. It can bind all 
three types of RARs, namely, α, β, and γ [13–15]. Tretinoin can be used alone or in combina-
tion with other agents. As it enhances the penetration of other drugs, it creates a synergistic 
effect in combined use. Different formulations of tretinoin molecule have been introduced 
including 0.025, 0.05, and 0.1% cream, 0.025 and 0.1 gel, 0.05% solution, microsphere gel, and 
polymer cream [13–16].
2.2.2. Adapalene
Adapalene is a third-generation retinoid. It is available in 0.1 and 0.3 % gel and 0.1% cream 
form [1–4, 13–15, 18].
2.2.3. Isotretinoin
13-cis retinoic acid is produced from the isomerization of retinoic acid. The effects and efficacy 
are similar to retinoic acids. Other than oral form, it is available in 0.05% gel, and 0.05 and 
0.1% cream form [1–4, 13–15].
2.2.4. Tazarotene
Tazarotene is a third-generation retinoid and its active metabolite is tazarotenic acid and it 
can bind all three types of RARs. It has not only anti-inflammatory effect like other retinoids, 
but also antiproliferative properties and normalizes the Filaggrin expression. Therefore, it is 
used also in the treatment of psoriasis. It is available in 0.05 and 0.1% cream form [1–4, 13–15].
2.2.5. Others
Retinaldehyde has a pivotal role in the natural vitamin A metabolism of keratinocytes. It is 
converted into all-trans retinoic acid and acts as topical retinoic acid in lower concentrations 
and generally found in cosmetic formulations. It has a mild comedolytic effect and has an 
antibacterial activity against Gram-positive bacteria including P. acnes due to its aldehyde 
group [19]. It is generally used in cosmetic formulations. Retinol and retinoic acid are metabo-
lized into retinoyl beta-glucuronide. Motretinid is a second-generation monoaromatic reti-
noid. The clinical and side effects of motretinid are less than tretinoin [1–4].
Tretinoin
13-cis retinoic acid (isotretinoin)
Adapalene
Tazarotene
Table 6. Topical retinoids used in the treatment of acne.




After the superiority of combining erythromycin 2% solution with 0.05% tretinoin to the 
monotherapy of each had been shown, fixed combination formulations of topical retinoids 
have been in production since 1978. Then, 0.025% tretinoid-4% erythromycin and 0.005% 
isotretinoin-2% erythromycin fixed combination formulations have been introduced [5]. It 
was reported that the usage of combination products were associated with better patient 
compliance. Recently, adapalene 0.1% and BPO 2.5% combination has been introduced. 
Theoretically, retinoid and BPO combination has been suggested to be advantageous due to 
the lack of bacterial resistance [1, 4, 13, 14].
2.2.7. The evaluation of comparative studies
Nast et al. conducted an evidence-based guideline for the treatment of acne in 2012 [7]. In this 
study, previous treatments were compared; superior efficacy was defined as a difference of 
more than 10% reduction of lesions in head-to-head comparisons.
2.2.7.1. Comedonal acne
Topical retinoids were found to show comparable-to-superior efficacy on noninflammatory 
lesions when compared to benzoyl peroxide [7].
Adapalene has shown comparable efficacy against noninflammatory lesions compared with 
tretinoin. Isotretinoin was effective as adapalene in the treatment of noninflammatory lesions, 
whereas it was found to be superior to tretinoin. Combination of adapalene and BPO shows 
a comparable-to-superior efficacy compared with BPO or adapalene alone. There was no trial 
comparing fixed-dose combinations of erythromycin and isotretinoin; however, using both 
erythromycin and isotretinoin was found to show comparable efficacy compared to erythro-
mycin or isotretinoin alone [7].
Fixed-dose combination of adapalene-BPO has shown comparable-to-superior efficacy com-
pared to adapalene or BPO alone, however, it was associated with lower patient tolerance [7].
2.2.7.2. Papulopustular acne
The efficacy of adapalene against inflammatory lesions was comparable to azelaic acid, BPO, 
tretinoin, and isotretinoin. Tretinoin was found to show comparable efficacy compared to 
isotretinoin. Fixed-dose combination of adapalene-BPO was superior to adapalene alone and 
was effective as BPO or clindamycin-BPO combination [7].
Combination of erythromycin and isotretinoin was superior to isotretinoin alone and was 
effective as erythromycin alone [7].
2.2.8. Patient tolerability and safety
Adapalene was found to display the best tolerability and safety among the topical retinoids 
followed by isotretinoin and tretinoin [7]. The tolerability and safety profile of fixed-dose 
adapalene-BPO preparation was lower than adapalene or BPO alone. The tolerability and 
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safety of erythromycin-isotretinoin combination was comparable to erythromycin or isotreti-
noin alone [7].
2.2.8.1. Factors affecting therapeutic compliance of patients
Treatment with less irritant topical retinoids was associated with better patient tolerance. To 
increase tolerance, it is advised to increase the dose gradually [5]. The carrier is also important 
as the active ingredient in topical formulation. Drugs with same active ingredient but differ-
ent carriers were reported to show different tolerability profile [6, 13]. As these factors affect 
patient compliance they even influence the efficacy of the drug. Therefore, preparations with 
less irritant properties are more effective due to increased patient adherence. The other factors 
involved in treatment compliance are cosmetic products and skin cleaning habits. Application 
of drying agents was associated with the increased side effects of topical products. Also, racial 
differences were reported to affect the tolerance to topical retinoids. Asians are more prone to 
the irritation effect of topical retinoids compared to Caucasians [1, 3, 6].
2.2.9. The safety profile of topical retinoids
The major side effects of topical retinoids are local skin reactions such as erythema, scaling, 
dryness, burning, and stinging; rarely, they can cause pustular eruption. In comparative stud-
ies, adapalene with lower irritation rates has showed better tolerability profile compared to 
tretinoin or isotretinoin. Patient preferred adapalene over tretinoin [1, 7, 13].
2.2.9.1. Safety in pregnancy and systemic absorption
Even in long-term usage local retinoids were absorbed percutaneously only 1–2% and found 
in the range of natural endogenous levels in plasma [13]. However, congenital anomalies 
have been reported after the usage of local retinoids in the first trimester [20]. On the other 
hand, according to two retrospective cohort study topical retinoic acids were found not to 
associate with minor malformations in first trimester [21, 22]. According to many studies, 
systemic absorption of 0.05 and 1% isotretinoin gel is negligible even in 12 times greater than 
the normal dose. Adapalene is a derivative of naphthoic acid. It contains methoxyphenyl ada-
mantyl chain and is stable against oxygen and light. Its cutaneous absorption is low due to 
its chemical structure. It could not be found in plasma after the application of 0.1% gel form 
[13]. In animal experiments, only systemic and high dose adapalene was reported to induce 
teratogenicity. However, as no studies have been carried out in pregnant subjects, potential 
risk cannot be excluded. In the literature, anophthalmia and abortion on 22nd week have 
been reported in a pregnant woman who used adapalene in 13th week of pregnancy [23]. 
Percutaneous absorption of tazarotene is less than 6%. No teratogenicity has been reported so 
far. Pregnancy category of tretinoin and adapalene is C, so they should be prescribed during 
pregnancy only if the potential benefit justifies potential risk to the fetus. On the other hand, 
erythromycin, azelaic acid, and BPO can be used during pregnancy, and retinoids are not rec-
ommended during pregnancy [13, 14, 24]. As no studies have been conducted on breastfeed-
ing women, they should be avoided during lactation period. The pregnancy category of oral 
isotretinoin and tazarotene is X and their topical formulations are contraindicatory [21, 22].




According to an investigation, dermatologists prescribe topical retinoids as second-line treat-
ment after clindamycin, oral minocycline, and topical BPO [25]. Since topical retinoids inhibit 
microcomedones that are the precursor lesions of acne, they are recommended in most forms 
of acne. In acne patients, microcomedones are observed histopathologically even in normal-
appearing skin. This underlines the fact that topical acne drugs can also be applied to normal-
appearing skin [26].
Mild, noninflammatory acne can be treated by topical retinoids alone. If the comedonal lesions 
present together with inflammatory lesions topical retinoids should be combined with anti-
microbial agents. As the combination treatment targets multiple pathophysiological factors, it 
is possible to get faster and permanent results. In the first-line treatment of moderate inflam-
matory acne, topical retinoids are recommended in combination with antimicrobial agents. 
Topical retinoids are the essential part of the maintenance treatment of acne [1–4, 13, 14].
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